Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2013

01-10-2013 | Original Article

Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting

Authors: A. Molassiotis, Z. Stamataki, E. Kontopantelis

Published in: Supportive Care in Cancer | Issue 10/2013

Login to get access

Abstract

Background

A number of risk factors have been implicated in the development of chemotherapy-induced nausea/vomiting (CINV). Our aim was to develop a risk prediction model and identify patients at high risk for developing CINV before their chemotherapy treatment.

Patients and methods

A multisite, observational, prospective longitudinal design was used. Participants were 336 chemotherapy-naïve cancer patients providing 791 assessments. They completed measures to assess potential risk factors for CINV, including socio-demographic and clinical/treatment-related characteristics, symptom distress, expectations for CINV and state–trait anxiety. CINV was measured with the MASCC Antiemesis Tool. Participants were divided randomly to a training set (=286) and a test set (=50). Random-effects models were run to ascertain the contribution of risk factors in the development of CINV using the training sample. Specificity and sensitivity of the model were assessed in both sets of samples.

Results

Younger age, history of nausea/vomiting, trait anxiety and fatigue were linked with higher levels of CINV, and use of moderately and low emetogenic chemotherapy were linked with lower CINV. The model's specificity were 55.4 and 50.0 % and sensitivity were 80.3 and 79.0 % in the training and test sample, respectively. A dynamic web-based tool is freely available for use by clinicians.

Conclusion

This model of risk prediction for CINV can be an aid to clinical decision-making and assist clinicians to rationalise antiemetic use with their patients.
Literature
1.
Glaus A, Knipping C, Morant R, Bohme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Husler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708–715CrossRefPubMed
2.
Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16(2):201–208CrossRefPubMed
3.
Molassiotis A, Farrell C, Bourne K, Brearley SG, Pilling M (2012) An exploratory study to clarify the cluster of symptoms predictive of chemotherapy-induced nausea using random forest modelling. J Pain Symptom Manage 44(5):692–703CrossRefPubMed
4.
Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227CrossRefPubMed
5.
Osoba D, Zee B, Warr D et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307–313CrossRefPubMed
6.
Rusthoven JJ, Osoba D, Butts CA et al (1998) The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Support Care Cancer 6:389–395CrossRefPubMed
7.
Farrell C, Brearley SG, Pilling M, Molassiotis A. The impact of chemotherapy-induced nausea on patients' nutritional status, psychological distress and quality of life. (accepted for publication, subject to minor corrections).
8.
Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA (2008) Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care 17:444–453CrossRef
9.
Molassiotis A, Brearley SG, Stamataki Z (2011) Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice. Support Care Cancer 19(7):949–956CrossRefPubMed
10.
Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F; on behalf of the PEER investigators. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 2012. [Epub ahead of print].
11.
Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS (2002) Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 10(2):139–145CrossRefPubMed
12.
Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P (2011) Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 19(10):1549–1563CrossRefPubMed
13.
Warr DG, Street JC, Carides AD (2011) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 19(6):807–813CrossRefPubMed
14.
Dranitsaris G, Joy A, Young S, Clemons M, Callaghan W, Petrella T (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool. I. Acute nausea and vomiting. J Support Oncol 7:W1–W8
15.
Petrella T, Clemons M, Joy A, Young S, Callaghan W, Dranitsaris G (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool. II. Delayed nausea and vomiting. J Support Oncol 7:W9–W16
16.
Nunnally JC (1978) Psychometric theory. McGraw-Hill, New York
17.
Roila F, Hesketh PJ, Herrstedt J (2006) Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20–28CrossRefPubMed
18.
Roscoe JA, Bushunow P, Morrow GR et al (2004) Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 101:2701–2708CrossRefPubMed
19.
Montgomery GH, Bovbjerg DH (2000) Pre-infusion expectations predict post-treatment nausea during repeated adjuvant chemotherapy infusions for breast cancer. Br J Health Psychol 5:105–119CrossRef
20.
Spielberger CD, Lushene RE. State trait anxiety inventory test manual. P.A.C.P Press. 1983.
21.
22.
Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage 34(2):148–159CrossRefPubMed
23.
Royston P (2005) Multiple imputation of missing values: Update of ice. Stata J 5(4):527–536
24.
Chatterjee S, Hadi AS (2006) Regression analysis by example, 4th edn. Wiley, HobokenCrossRef
25.
Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18(9):1171–1177CrossRefPubMed
26.
Shih V, Wan HS, Chan A (2009) Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother 43(3):444–452CrossRefPubMed
27.
Koffman J, Higginson IJ, Donaldson N (2003) Symptom severity in advanced cancer, assessed in two ethnic groups by interviews with bereaved family members and friends. J R Soc Med 96(1):10–6CrossRefPubMed
28.
Xu L, Koch KL, Summy-Long J, Stern RM, Seaton JF (1993) Hypothalamic and gastric myoelectrical responses during vection-induced nausea in healthy Chinese subjects. Am J Physiol 265:E578–584PubMed
Metadata
Title
Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting
Authors
A. Molassiotis
Z. Stamataki
E. Kontopantelis
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1843-2

Other articles of this Issue 10/2013

Supportive Care in Cancer 10/2013 Go to the issue

Original Article

Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1

Original Article

Developing competencies for multidisciplinary hospice and palliative care professionals in Korea

Original Article

A Pan-Canadian practice guideline: prevention, screening, assessment, and treatment of sleep disturbances in adults with cancer

Original Article

FIT false-positives in colorectal cancer screening experience psychological distress up to 6 weeks after colonoscopy

Original Article

Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital

Original Article

Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits